The role of fibrosis in Duchenne muscular dystrophy
- PMID: 23620650
- PMCID: PMC3631802
The role of fibrosis in Duchenne muscular dystrophy
Abstract
Muscular dystrophies such as Duchenne muscular dystrophy (DMD) are usually approached as dysfunctions of the affected skeletal myofibres and their force transmission. Comparatively little attention has been given to the increase in connective tissue (fibrosis) which accompanies these muscular changes. Interestingly, an increase in endomysial tissue is apparent long before any muscular degeneration can be observed. Fibrosis is the result of a reactive or reparative process involving mechanical, humoral and cellular factors. Originating from vulnerable myofibres, muscle cell necrosis and inflammatory processes are present in DMD. Muscular recovery is limited due to the limited number and capacity of satellite cells. Hence, a proactive and multimodal approach is necessary in order to activate protective mechanisms and to hinder catabolic and tissue degrading pathways. Several avenues are discussed in terms of potential antifibrotic therapy approaches. These include pharmaceutical, nutritional, exercise-based and other mechanostimulatory modalities (such as massage or yoga-like stretching) with the intention of exerting an anti-inflammatory and antifibrotic effect on the affected muscular tissues. A preventive intervention at an early age is crucial, based on the early and seemingly non-reversible nature of the fibrotic tissue changes. Since consistent assessment is essential, different measurement technologies are discussed.
Keywords: Duchenne muscular dystrophy; TGF-β1; antifibrotic therapy; endo- and perimysium; extracellular matrix; fibrosis; myostatin.
Figures




Similar articles
-
Connective tissue cells expressing fibro/adipogenic progenitor markers increase under chronic damage: relevance in fibroblast-myofibroblast differentiation and skeletal muscle fibrosis.Cell Tissue Res. 2016 Jun;364(3):647-660. doi: 10.1007/s00441-015-2343-0. Epub 2016 Jan 7. Cell Tissue Res. 2016. PMID: 26742767
-
A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy.Muscle Nerve. 2012 Jun;45(6):803-14. doi: 10.1002/mus.23341. Muscle Nerve. 2012. PMID: 22581532
-
Abnormal NFAT5 Physiology in Duchenne Muscular Dystrophy Fibroblasts as a Putative Explanation for the Permanent Fibrosis Formation in Duchenne Muscular Dystrophy.Int J Mol Sci. 2020 Oct 24;21(21):7888. doi: 10.3390/ijms21217888. Int J Mol Sci. 2020. PMID: 33114289 Free PMC article.
-
Duchenne and Becker muscular dystrophy: Cellular mechanisms, image analysis, and computational models: A review.Cytoskeleton (Hoboken). 2024 Jun-Jul;81(6-7):269-286. doi: 10.1002/cm.21826. Epub 2024 Jan 15. Cytoskeleton (Hoboken). 2024. PMID: 38224155 Review.
-
Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.Matrix Biol. 2018 Aug;68-69:616-627. doi: 10.1016/j.matbio.2018.02.016. Epub 2018 Feb 23. Matrix Biol. 2018. PMID: 29481844 Free PMC article. Review.
Cited by
-
Oxidative muscles have better mitochondrial homeostasis than glycolytic muscles throughout life and maintain mitochondrial function during aging.Aging (Albany NY). 2018 Nov 18;10(11):3327-3352. doi: 10.18632/aging.101643. Aging (Albany NY). 2018. PMID: 30449736 Free PMC article.
-
A negative feedback loop between fibroadipogenic progenitors and muscle fibres involving endothelin promotes human muscle fibrosis.J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1771-1784. doi: 10.1002/jcsm.12974. Epub 2022 Mar 22. J Cachexia Sarcopenia Muscle. 2022. PMID: 35319169 Free PMC article.
-
Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models.Nat Commun. 2023 Aug 15;14(1):4909. doi: 10.1038/s41467-023-40555-9. Nat Commun. 2023. PMID: 37582915 Free PMC article.
-
Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy.Sci Adv. 2022 Jan 28;8(4):eabh4423. doi: 10.1126/sciadv.abh4423. Epub 2022 Jan 28. Sci Adv. 2022. PMID: 35089797 Free PMC article.
-
The Adiponectin Receptor Agonist, ALY688: A Promising Therapeutic for Fibrosis in the Dystrophic Muscle.Cells. 2023 Aug 19;12(16):2101. doi: 10.3390/cells12162101. Cells. 2023. PMID: 37626911 Free PMC article.
References
-
- Duchenne GB. Recherches sur la paralysie musculaire pseudo- hypertrophique ou paralysie myosclerosique. Arch Gen Ned. 1868;11:5–552. 5,178,305,421,552.
-
- Emery AEH, Emery MLH. Duchenne muscular dystrophy or Meryon's disease. 2nd ed. Oxford: Oxford University Press; 2011.
-
- Bell CD, Conen PE, et al. Histopathological changes in Duchenne muscular dystrophy. J Neurol Sci. 1968;7:529–544. - PubMed
-
- Duance VC, Stephens HR, Dunn M, et al. A role for collagen in the pathogenesis of muscular dystrophy? Nature. 1980;284:470–471. - PubMed
-
- Desguerre I, Mayer M, Leturcq F, et al. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol. 2009;68:762–773. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources